Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Abstract
Combined MAPK pathway inhibition using dual BRAF and MEK inhibitors has prolonged the duration of clinical response in patients with BRAFV600E-driven tumors compared with either agent alone. However, resistance frequently arises.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2019
- Source ID
- 10.1158/1078-0432.ccr-18-2779
Entities
People
- Anatoly Urisman
- Catherine Wilson
- David Carbone
- Dennie T. Frederick
- Eva Lin
- Frank McCormick
- Jeff Settleman
- Keith T. Flaherty
- Piro Lito
- Rene Bernards
- Victoria E. Wang
- Yaohua Xue
- Yi Cao
Organizations
- American Society of Clinical Oncology
- Cornell University
- Genentech
- Memorial Sloan Kettering Cancer Center
- National Institutes of Health
- United States Department of Defense
- University of California
- University of California, San Francisco